MELBOURNE, Australia, May 8, 2023 (GLOBE NEWSWIRE) — Opthea Limited optopt)), a clinical-stage biopharmaceutical company developing novel therapies to treat common and progressive retinal diseases, today announced that Timothy E. Morris, the company’s Chief Financial Officer, will speak at the JMP Securities Life Sciences Conference in May in New York City will give a lecture 15-16 2023.
Mr.Morris will be presenting on Tuesday May 16thth at 1:00 p.m. ET (3:00 p.m. on the 17thth AEDT), which you can access live by registering at https://wsw.com/webcast/jmp59/opt/1565103. An archive of the presentation will be accessible for 90 days on the Investors page of Opthea’s website at https://www.opthea.com/presentations/.
About Opthea Limited
Opthea (optopt is a biopharmaceutical company developing novel therapies to address unmet needs in the treatment of common and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Opthea’s lead product candidate, OPT-302, is in pivotal Phase 3 clinical trials and is being developed for use in combination with anti-VEGF-A monotherapies to achieve broader inhibition of the VEGF family with the goal to improve overall efficacy and demonstrate superior vision gains that can be achieved by inhibiting VEGF-A alone.
Risks Inherent in Investing in Biotechnology Companies
The development of pharmaceutical products to market maturity has a number of inherent risks. The lengthy clinical trial process is designed to evaluate a drug’s safety and efficacy before it is placed on the market, and a significant proportion of drugs fail to meet one or both of these criteria. Other risks include uncertainty of patent protection and proprietary rights, whether patent applications and issued patents provide adequate protection to enable product development, obtaining the necessary drug regulatory approvals, and difficulties posed by rapid…
[ad_2]
Source story
